Product Description
AJ302 is a novel selective histone deacetylase 6 inhibitor (HDAC6i) under development for the prevention and/or treatment of chemotherapy-induced peripheral neuropathy (CIPN). AJ302, selected for its safety profile and drug-like physiochemical properties, substantially reduces drug toxicity commonly associated with non-selective HDAC inhibitors that deacetylate histone proteins in the genome. Recent studies have indicated that HDAC6 may be a drug target for the protection and regeneration of damaged peripheral nerves by enhancing microtubule-based axonal transport and mitochondrial dynamics. Scientists at AnnJi have demonstrated that AJ302 increases a-tubulin acetylation in microtubule, promotes neurite outgrowth and branching in paclitaxel-induced dorsal root ganglion (DRG) neurons in vitro. In a rat model of CIPN, AJ302 was shown to reverse paclitaxel-induced mechanical allodynia in a dose-dependent manner. The improvement in sensory functions was sustained after the treatment stopped. (Sourced from: https://www.ajpharm.com/aj302-page/#:~:text=AJ302%20is%20a%20novel%20selective,induced%20peripheral%20neuropathy%20(CIPN).)
Mechanisms of Action: HDAC6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AnnJi Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|